REGN15505
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 06, 2026
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
(clinicaltrials.gov)
- P1/2 | N=265 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Castration-Resistant Prostate Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • PD-L1
May 19, 2026
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
(clinicaltrials.gov)
- P1/2 | N=265 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
New P1/2 trial • Castration-Resistant Prostate Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • PD-L1
1 to 2
Of
2
Go to page
1